Shares of Galectin Therapeutics Inc (NASDAQ:GALT) have received an average broker rating score of 0.00 () from the three brokers that provide coverage for the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong sell recommendation and two have issued a hold recommendation on the company.
Brokers have set a 12-month consensus target price of $1.12 for the company, according to Zacks. Zacks has also given Galectin Therapeutics an industry rank of 93 out of 265 based on the ratings given to its competitors.
Several equities analysts have recently commented on the company. FBR & Co reiterated a “market perform” rating and set a $2.00 price objective on shares of Galectin Therapeutics in a research report on Monday, February 6th. Zacks Investment Research lowered Galectin Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, January 16th.
WARNING: This report was first published by Mideast Time and is the sole property of of Mideast Time. If you are viewing this report on another domain, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this report can be accessed at https://www.mideasttime.com/galectin-therapeutics-inc-galt-given-average-rating-of-by-brokerages/1589924.html.
Shares of Galectin Therapeutics (NASDAQ:GALT) opened at 2.33 on Tuesday. The company’s market capitalization is $68.49 million. The firm has a 50-day moving average price of $1.76 and a 200-day moving average price of $1.25. Galectin Therapeutics has a one year low of $0.49 and a one year high of $3.05.
Several institutional investors have recently made changes to their positions in the stock. Courage Capital Management LLC purchased a new position in shares of Galectin Therapeutics during the third quarter valued at approximately $147,000. Benchmark Capital Advisors raised its position in shares of Galectin Therapeutics by 98.3% in the third quarter. Benchmark Capital Advisors now owns 118,200 shares of the company’s stock valued at $134,000 after buying an additional 58,600 shares during the period. Finally, Advisor Group Inc. raised its position in shares of Galectin Therapeutics by 3.8% in the third quarter. Advisor Group Inc. now owns 413,125 shares of the company’s stock valued at $467,000 after buying an additional 15,200 shares during the period. Hedge funds and other institutional investors own 10.01% of the company’s stock.
Galectin Therapeutics Company Profile
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Galectin Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.